Status:
COMPLETED
Protein Kinase 2 (HIPK2) Polymorphisms on rs2058265, rs6464214, and rs7456421
Lead Sponsor:
Saglik Bilimleri Universitesi
Conditions:
Kidney Stone
Eligibility:
All Genders
38-68 years
Phase:
NA
Brief Summary
In the present study investigators aimed to investigate whether homeodomain interacting protein kinase 2 (HIPK2) polymorphism is associated with renal stone formation in Turkish population or not. On...
Detailed Description
Kidney stone incidence depends on geographical, climatic, ethnic, dietary and genetic factors. Thus the prevalence rates for urinary stones change from 1% to 20%. 1,2 Genetic polymorphism also causes ...
Eligibility Criteria
Inclusion
- Patients with nephrolithiasis
Exclusion
- Patients had a history of chronic urinary tract infection
- renal failure
- gastrointestinal diseases
- increased levels of vitamin D
- sarcoidosis
- primary hyperoxaluria
- polycystic kidney disease, gout, renal tubular acidosis, primary and secondary hyperparathyroidism.
Key Trial Info
Start Date :
August 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 6 2019
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT04804436
Start Date
August 1 2018
End Date
October 6 2019
Last Update
March 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Omer Gokhan Doluoglu
Ankara, Turkey (Türkiye)